| Basics |
| Company: |
Tango Therapeutics, Inc. |
| IPO Date: |
September 3, 2020 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$253.51M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.26 | 3.60%
|
| Avg Daily Range (30 D): |
$0.11 | 3.75%
|
| Avg Daily Range (90 D): |
$0.15 | 4.05%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.54M |
| Avg Daily Volume (30 D): |
.62M |
| Avg Daily Volume (90 D): |
1.34M |
| Trade Size |
| Avg Trade Size (Sh.): |
106 |
| Avg Trade Size (Sh.) (30 D): |
100 |
| Avg Trade Size (Sh.) (90 D): |
148 |
| Institutional Trades |
| Total Inst.Trades: |
517 |
| Avg Inst. Trade: |
$1.62M |
| Avg Inst. Trade (30 D): |
$1.13M |
| Avg Inst. Trade (90 D): |
$1.46M |
| Avg Inst. Trade Volume: |
.22M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.51M |
| Avg Closing Trade (30 D): |
$.76M |
| Avg Closing Trade (90 D): |
$1.01M |
| Avg Closing Volume: |
192.41K |
|
|
|
|
| News |
Jun 14, 2024 @ 9:10 AM
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will...
Source: Zacks Equity Research
|
May 24, 2024 @ 3:01 PM
Forecasting The Future: 4 Analyst Projections For ...
Source: Benzinga Insights
|
May 8, 2024 @ 12:10 PM
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, M...
Source: Zacks Equity Research
|
May 7, 2024 @ 2:00 PM
Will Tango Therapeutics, Inc. (TNGX) Report Negati...
Source: Zacks Equity Research
|
Mar 18, 2024 @ 12:10 PM
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, L...
Source: Zacks Equity Research
|
| Financials |
| |
TTM |
Q2 2024 |
Q1 2024 |
|
Basic EPS
|
$-.27
|
$-.24
|
$-.35
|
|
Diluted EPS
|
$-.27
|
$-.24
|
$-.35
|
|
Revenue
|
$ 11.61M
|
$ 19.88M
|
$ 6.47M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -29.17M
|
$ -25.55M
|
$ -37.91M
|
|
Operating Income / Loss
|
$ -32.88M
|
$ -29.55M
|
$ -42.26M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 1.58M
|
$ -9.6M
|
$ -6.08M
|
|
PE Ratio
|
|
|
|
|
